NecLife plans Rs 220-cr expansion in Punjab

Chandigarh-based Nectar Lifesciences Ltd (NecLife), an integrated pharmaceutical organisation offering comprehensive range of cephalosporin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), has plans to expand its capacity at the Derabassi facility with an investment of Rs 220 crore. Further, it has plans to foray into the US and Europe market by the next year.

The company has manufacturing facility at Derabassi (Punjab) for producing oral and sterile active pharmaceutical ingredients (APIs) and formulations, spread over 60 acres of land.

Also, it has one more unit in Baddi (Himachal Pradesh) to manufacture formulations, spread over 10 acres.

The company plans to increase the production capacity by 200 tonnes per year at its Derabassi facility. After the expansion, the total capacity would reach 650 tonnes per year. Also, it plans to increase its menthol capacity at the exiting premises in Derabassi.

Speaking to Business Standard, Chief Executive Officer Dinesh Dua said, "We have plans to increase our production capacity at Derabassi unit. Besides, we plan to expand R&D facility at the existing premises. Further, we will increase our cogeneration capacity from 8 Mw to 14 Mw. We have earmarked Rs 220 crore to undertake these expansion programmes."